# A Study of NB003 in Patients With Advanced Malignancies

> **NCT04936178** · PHASE1 · COMPLETED · sponsor: **Ningbo Newbay Technology Development Co., Ltd** · enrollment: 258 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** NB003 tablets

## Key facts

- **NCT ID:** NCT04936178
- **Lead sponsor:** Ningbo Newbay Technology Development Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-06
- **Primary completion:** 2025-08-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 258 (ACTUAL)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04936178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04936178, "A Study of NB003 in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT04936178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*